Intrinsiqs

Is First Tracks Biotherapeutics Inc overvalued?

First Tracks Biotherapeutics Inc (TRAX) — key valuation metrics and fundamentals.

No verdict
Price
$36.65
Fair value
—
Current P/E
—
Normal P/E
—
Market cap
$1.28B
Dividend yield
0.0%
Return on equity
-47.4%
Sector
Healthcare

See the full interactive analysis →

Fair value compares TRAX's current P/E to its own historical "normal" P/E (FAST Graphs-style). Updated 24 Sep 2026.